Article
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Cancer genetics - 1 Nov 2022
Wong Newton A C S, Garcia-Petit Christel, Dangoor Adam, Andrew Nicola
Abstract excerpt
It is well recognized that the primary KIT or PDGFRA variant of a gastrointestinal stromal tumour (GIST) can predict sensitivity to imatinib. However, these data are currently spread across a wide range of publications and have not been collated as one reference. A broad-ranging literature search was therefore performed to assemble such a database which should help optimize imatinib-based management of GIST...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.